INT280052

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.72
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) DNA binding (Zglp1)
peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Dpp4 (Mus musculus)
Zglp1 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 33 100.00 Very High Very High Very High
cytokine 2 5.00 Very Low Very Low Very Low
ischemia 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Inflammatory marker 1 5.00 Very Low Very Low Very Low
Neuropeptide 1 5.00 Very Low Very Low Very Low
abdominal pain 1 5.00 Very Low Very Low Very Low
Paracetamol 1 5.00 Very Low Very Low Very Low
rheumatoid arthritis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 103 99.14 Very High Very High Very High
Coronary Artery Disease 1 86.24 High High
Increased Venous Pressure Under Development 2 83.60 Quite High
Myocardial Infarction 2 62.84 Quite High
Monsters 1 45.76 Quite Low
Hypoglycemia 30 5.00 Very Low Very Low Very Low
Weight Loss 14 5.00 Very Low Very Low Very Low
Body Weight 12 5.00 Very Low Very Low Very Low
Vomiting 10 5.00 Very Low Very Low Very Low
Obesity 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The encouraging outcomes of studies of GLP-1 administration in T2DM have led to the development of drugs that enhance GLP-1 activity: synthetic long-acting agonists (such as exenatide and liraglutide) that are resistant to degradation by DPP-IV and could thus be administered less frequently, and inhibitors of DPP-IV (such as sitagliptin and vildagliptin) that increase endogenous GLP-1 levels.
Negative_regulation (inhibitors) of DPP-IV Positive_regulation (enhance) of GLP-1 associated with diabetes mellitus and agonist
1) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.72 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox